ADIAL PHARMACEUTICALS, INC. (ADIL) - Dilution Analysis

10-Q filing | 2.1M shares outstanding

S-3 filing: This prospectus relates to the resale from time to time of up to 13,823,512 shares of common stock of Adial Pharmaceuticals, Inc. by the Selling Stockholder.

10-Q filing | 22.2M shares outstanding

10-Q filing | 21.8M shares outstanding

8-K filing: Adial Pharmaceuticals, Inc. consummated a best efforts offering of common stock and warrants, resulting in gross proceeds of approximately $3.6 million. ($3.6M proceeds)

8-K filing: Adial Pharmaceuticals, Inc. consummated a best efforts offering of 5,341,200 shares of common stock, pre-funded warrants to purchase up to 5,758,800 shares of common stock, Series D warrants to purchase up to 11,100,000 shares of common stock and Series E warrants to purchase up to 8,325,000 shares of common stock, resulting in gross proceeds of approximately $3.6 million. ($3.6M proceeds)

S-1/A filing: This S-1/A filing relates to an offering of common stock, pre-funded warrants, and common warrants, with the net proceeds intended for working capital and general corporate purposes.

S-1 filing: This is an S-1 filing for an offering of Common Stock, Pre-Funded Warrants, and Common Warrants by Adial Pharmaceuticals, Inc.

S-3 filing: This prospectus relates to the resale from time to time of up to 6,730,376 shares of common stock of Adial Pharmaceuticals, Inc. by the Selling Stockholders.

10-Q filing | 7.9M shares outstanding

10-K filing | 6.6M shares outstanding

S-1 filing: This S-1 filing relates to the offering and resale by Alumni Capital LP of up to 5,000,000 shares of Adial Pharmaceuticals, Inc.'s common stock, which includes 68,807 commitment shares, and the potential sale of common stock to Alumni Capital for up to $5 million.

8-K filing: Adial Pharmaceuticals, Inc. entered into a Purchase Agreement with Alumni Capital LP, where the Company has the right to sell up to $5,000,000 (potentially increasing to $10,000,000) of newly issued common stock to Alumni Capital, with sales at the Company's option and subject to certain conditions and limitations.

10-Q filing | 5.8M shares outstanding

10-Q filing | 6.4M shares outstanding

10-Q filing | 4.2M shares outstanding

S-3 filing: This is an S-3 filing for the resale of up to 2,369,000 shares of common stock by selling stockholders, consisting of shares issuable upon exercise of Series C Common Warrants and Placement Agent Warrants. The company will not receive any proceeds from the sale of these shares but will receive proceeds from any cash exercise of the warrants.

10-K filing | 4.1M shares outstanding

8-K filing: Adial Pharmaceuticals, Inc. entered into a warrant inducement agreement with a holder to exercise existing warrants for 1,150,000 shares of common stock at $2.82 per share, resulting in gross proceeds of approximately $3.5 million, and issued new warrants to purchase 2,300,000 shares of common stock. ($3.5M proceeds)

S-3 filing: Adial Pharmaceuticals, Inc. files an S-3 to offer and sell up to $100,000,000 of any combination of their common stock, preferred stock, debt securities, warrants or units.

10-Q filing | 1.2M shares outstanding

S-1 filing: This S-1 filing relates to the resale of up to 4,340,426 shares of Common Stock of Adial Pharmaceuticals, Inc. by selling stockholders.

10-Q filing | 1.2M shares outstanding

8-K filing: Stock split 1-for-25 | Outstanding: 26,463,559 → 1

S-1/A filing: This S-1/A filing relates to the offering and resale of up to 1,740,990 shares of common stock by Alumni Capital LP and the potential sale of common stock to Alumni Capital LP for proceeds of up to $3 million.

S-1 filing: This is an S-1 filing for the offering and resale of up to 10,199,620 shares of common stock by Alumni Capital LP, and the potential sale of common stock to Alumni Capital for up to $3 million.

8-K filing: Adial Pharmaceuticals, Inc. entered into a purchase agreement with Alumni Capital LP, allowing the company to sell up to $3,000,000 (potentially increasing to $10,000,000) of newly issued common stock, with Alumni Capital receiving 199,620 shares as a commitment fee.

10-Q filing | 26.5M shares outstanding

10-K filing | 28.5M shares outstanding

8-K filing: Adial Pharmaceuticals, Inc. entered into a master services agreement with The Keswick Group, LLC, where Tony Goodman, a director of the Company, is the founder and principal. The Keswick Group, LLC will serve as a business consultant and may receive a performance bonus of 100,000 shares of the Company's restricted common stock upon completion of a partnering agreement for AD04.

8-K filing: Adial Pharmaceuticals, Inc. closed its at-the-market registered direct offering of 1,829,269 shares of common stock at $0.41 per share with a single institutional investor for gross proceeds of $0.75 million. ($0.0M proceeds)

8-K filing: Adial Pharmaceuticals, Inc. entered into a securities purchase agreement for the issuance of 1,829,269 shares of common stock to an accredited institutional investor for approximately $750,000 in a registered direct offering. ($0.75M proceeds)

8-K filing: Adial Pharmaceuticals, Inc. entered into an Option Agreement with Adenomed LLC for the potential acquisition of Purnovate, Inc., a wholly-owned subsidiary of Adial, involving cash payments, equity issuance in Buyer, and assumption of certain liabilities.

10-Q filing | 25.7M shares outstanding

10-Q filing | 24.3M shares outstanding

POS AM filing: This prospectus relates to the offer and sale of up to 1,575,112 shares of common stock underlying warrants previously issued by Adial Pharmaceuticals, Inc.

POS AM filing: This prospectus relates to the offer and sale of up to 2,133,750 shares of common stock underlying warrants previously issued by Adial Pharmaceuticals, Inc.

10-Q filing | 23.8M shares outstanding

S-3/A filing: This is an S-3/A filing including a form of common stock warrant.

10-K filing | 23.7M shares outstanding

S-3 filing: This prospectus relates to the resale from time to time, by the selling stockholder of up to 3,977,888 shares of common stock, par value $.001, issuable upon exercise of certain outstanding warrants.

8-K filing: Adial Pharmaceuticals entered into a securities purchase agreement with an investor to issue shares of common stock, pre-funded warrants, and warrants for an aggregate purchase price of approximately $10 million. ($10.0M proceeds)

8-K filing: Adial Pharmaceuticals, Inc. closed the second tranche of its private offering on December 17, 2021, with Bespoke Growth Partners, Inc. purchasing 180,000 shares of common stock at $4.00 per share, resulting in proceeds of $720,000 for the Company. ($0.8M proceeds)

S-3 filing: This S-3 filing relates to the resale from time to time of up to 200,000 shares of Adial Pharmaceuticals, Inc. common stock by the selling stockholder.

10-Q filing | 20.8M shares outstanding

8-K filing: Adial Pharmaceuticals, Inc. entered into a Securities Purchase Agreement with Bespoke Growth Partners, Inc., where Bespoke purchased an initial 20,000 shares of the Company's common stock at $4.00 per share. ($0.08M proceeds)

8-K filing: Adial Pharmaceuticals, Inc. released 200,000 shares of its common stock and 150,000 warrants from a Lock-Up Agreement to permit the sale of such shares and warrants to BesSpoke Growth Partners, Inc. in a private transaction.

10-Q filing | 20.3M shares outstanding

8-K filing: Adial Pharmaceuticals, Inc. closed the second tranche of its private offering of common stock on August 3, 2021 and August 4, 2021, selling shares to Bespoke Growth Partners, Inc., Keystone Capital Partners, LLC, and Richard Gilliam at $3.00 per share for gross proceeds of $4,500,000. ($4.5M proceeds)

S-3 filing: This S-3 filing registers 1,666,668 shares of common stock for resale by selling stockholders.

8-K filing: Adial Pharmaceuticals, Inc. entered into Securities Purchase Agreements with investors for an aggregate investment of $5,000,000 in consideration of the purchase by such investors of an aggregate of 1,666,667 shares of the Company's common stock at a purchase price of $3.00 per share. ($0.5M proceeds)

RW filing: Adial Pharmaceuticals requests the withdrawal of their registration statement because they no longer wish to conduct a public offering of securities at this time.

S-1/A filing: The company is offering 6,968,641 shares of common stock at an assumed price of $2.87 per share.

8-K filing: Adial Pharmaceuticals, Inc. closed the second tranche of its private offering of common stock on June 1, 2021, with Bespoke Growth Partners, Inc. purchasing 303,000 shares and Keystone Capital Partners, LLC purchasing 300,000 shares at $3.00 per share, resulting in proceeds of $1,809,000. ($1.81M proceeds)

S-1 filing: The company is offering common stock and has granted the underwriters an over-allotment option. The net proceeds from this offering will be approximately $18.3 million ($21.1 million if the underwriter fully exercises its overallotment option) and will be used for working capital purposes, acquisitions and other strategic purposes.

S-3 filing: This prospectus relates to the resale from time to time of up to 699,980 shares of Adial Pharmaceuticals, Inc. common stock by the selling stockholders identified in this prospectus.

10-Q filing | 17.5M shares outstanding

S-3 filing: This prospectus relates to the resale from time to time of up to 700,001 shares of Adial Pharmaceuticals, Inc. common stock by the selling stockholders.

8-K filing: Dr. Bankole Johnson sold 150,000 shares of Adial Pharmaceuticals common stock in a private transaction at a price of $2.50 per share to an unaffiliated third party. ($0.38M proceeds)

POS AM filing: This prospectus relates to the offer and sale of up to 2,133,750 shares of common stock underlying warrants previously issued by Adial Pharmaceuticals, Inc.

POS AM filing: This is a prospectus for the offer and sale of up to 1,575,112 shares of common stock underlying warrants previously issued by Adial Pharmaceuticals.

10-K filing | 14.4M shares outstanding

8-K filing: Adial Pharmaceuticals, Inc. entered into Securities Purchase Agreements with Bespoke Growth Partners, Inc., entities controlled by James W. Newman, Jr., and Keystone Capital Partners, LLC for the sale of common stock at $3.00 per share. ($2.1M proceeds)

8-K filing: Adial Pharmaceuticals, Inc. acquired Purnovate, LLC on January 26, 2021, through an Equity Purchase Agreement, paying $350,000 in cash and issuing 700,000 shares of restricted common stock to the Members of Purnovate.

8-K filing: Adial Pharmaceuticals, Inc. entered into an Equity Purchase Agreement with Purnovate, LLC to purchase all of the outstanding membership interests of Purnovate, issuing 700,000 shares of Adial restricted common stock to the members of Purnovate in exchange for the acquisition.

S-1 filing: This S-1 filing outlines information regarding Adial Pharmaceuticals, Inc. including their focus on developing AD04 for the treatment of alcohol use disorder, their Keystone Capital transaction allowing them to sell up to $15,000,000 in common stock, and information regarding warrants issued in their IPO.

8-K filing: Adial Pharmaceuticals, Inc. entered into a Common Stock Purchase Agreement with Keystone Capital Partners, LLC, allowing the Company to sell up to $15,000,000 of newly issued shares of common stock to Keystone Capital, and issued 175,000 commitment shares.

10-Q filing | 14.2M shares outstanding

8-K filing: Adial Pharmaceuticals, Inc. received notice of exercise of previously issued warrants to purchase 225,000 shares of the Company's common stock for aggregate proceeds of $450,000. ($0.45M proceeds)

8-K filing: Adial Pharmaceuticals sold 357,143 restricted shares of common stock to Bespoke Growth Partners, Inc. for an aggregate purchase price of $500,000.20 on September 21, 2020. ($0.5M proceeds)

8-K filing: Dr. Bankole Johnson sold 350,000 shares of Adial Pharmaceuticals, Inc. common stock to an unaffiliated third-party in a private transaction after being released from Lock-Up restrictions to fund his new clinic.

10-Q filing | 13.4M shares outstanding

S-1 filing: This S-1 filing relates to the resale of up to 2,115,000 shares of common stock issuable upon exercise of certain outstanding warrants issued in a private placement.

8-K filing: Adial Pharmaceuticals, Inc. closed a registered direct offering of 2,820,000 shares of common stock and warrants to purchase up to 2,115,000 shares, for gross proceeds of $5,217,000. ($5.22M proceeds)

8-K filing: Adial Pharmaceuticals, Inc. entered into a securities purchase agreement for the issuance of 2,820,000 shares of common stock and warrants to purchase up to 2,115,000 shares at an exercise price of $2.00 per share for an aggregate purchase price of $5,217,000. ($5.22M proceeds)

10-Q filing | 10.6M shares outstanding

S-3 filing: The filing is an S-3 registration statement for common stock which may be offered and sold from time to time.

POS AM filing: This prospectus relates to the offer and sale of up to 2,133,750 shares of common stock underlying warrants previously issued by Adial Pharmaceuticals, Inc.

POS AM filing: This prospectus relates to the offer and sale of up to 1,575,112 shares of common stock underlying warrants previously issued by us that are issuable at a price of $6.25 per share from time to time upon exercise of outstanding warrants issued to investors and the underwriters in our initial public offering.

10-K filing | 6.9M shares outstanding